Kelly Kugler

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

Mark G. Kris, Bruce E. Johnson, Lynne D. Berry et al. · JAMA · 2014 · 1.7K citations

Medicine, Genetics, Oncology +17

Multi-institutional Oncogenic Driver Mutation Analysis in Lung Adenocarcinoma: The Lung Cancer Mutation Consortium Experience

Lynette M. Sholl, Dara L. Aisner, Marileila Varella‐Garcia et al. · Journal of Thoracic Oncology · 2015 · 430 citations · Full text

Medicine, Genetics, Oncology +16

The Impact of Smoking and TP53 Mutations in Lung Adenocarcinoma Patients with Targetable Mutations—The Lung Cancer Mutation Consortium (LCMC2)

Dara L. Aisner, Lynette M. Sholl, Lynne D. Berry et al. · Clinical Cancer Research · 2017 · 218 citations · Full text

Medicine, Genetics, Oncology +16

Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC).

Mark G. Kris, B. E. Johnson, D J Kwiatkowski et al. · Journal of Clinical Oncology · 2011 · 214 citations

Medicine, Genetics, Oncology +17

Clinicopathologic features and outcomes of patients with lung adenocarcinomas harboring <scp><i>BRAF</i></scp> mutations in the <scp>L</scp>ung <scp>C</scp>ancer <scp>M</scp>utation <scp>C</scp>onsortium

Liza C. Villaruz, Mark A. Socinski, Shira Abberbock et al. · Cancer · 2014 · 122 citations · Full text

Medicine, Molecular Genetics, Oncology +17